HURA - NASDAQ

TuHURA Biosciences, Inc.

HURA·NASDAQ

$2.12

+2.4%

HealthcareBiotechnology

TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$135.01M

EPS-0.6300

P/E Ratio-3.37

Earnings Date08/13/2026

27.35M

Assets

37%

3Y+80.0%

5Y+102.0%

10Y+246.0%

6.42M

Total Liabilities

20%

3Y+122.0%

5Y+117.0%

10Y+382.0%

20.93M

Total Equity

43%

3Y+70.0%

5Y+98.0%

10Y+218.0%

TuHURA Biosciences, Inc. Funding & Solvency Profile

HURA · NASDAQ

Current Assets

Cash & Cash Equivalents3.62M

Net Receivables0.00

Inventory0.00

Other Current Assets1.00M

Total Current Assets5 M

Non-Current Assets

Property, Plant & Equipment685.17K

Goodwill & Intangible Assets10.74M

Long-Term Investments0.00

Other Non-Current Assets11.31M

Total Non-Current Assets12 M

Total Assets

27.35M

Financial Health Analysis

Current Ratio

0.78x

Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.

Debt-to-Equity Ratio

0.31x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

-1298146

Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.

Asset Composition

17% Current

Capital-intensive business with significant long-term investments in property, equipment, or intangibles.

Financial Health Insight

Conservative with tight liquidity: Low debt is positive, but current ratio warrants attention. Consider whether the company is efficiently deploying its equity capital.

TuHURA Biosciences, Inc. Balance Sheet

HURA • NASDAQ

TuHURA Biosciences, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Jun 2021	Jun 2020	Jun 2019	Jun 2018	Jun 2017	Jun 2016	Jun 2015	Dec 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	3.6M	12.7M	3.7M	14.3M	5.5M	10.5M	2.4M	3.7M	6M	6.6M	6.2M	1.8M	4.1M
Cash & Short-Term Investments	3.6M	12.7M	3.7M	14.3M	5.5M	10.5M	2.4M	3.7M	6M	6.6M	6.2M	1.8M	4.1M
Net Receivables	0.0	222.7K	334.4K	101.4K	0.0	0.0	0.0	26.2K	39.5K	76.6K	18.4K	25.8K	11.1K
Accounts Receivables	0.0	0.0	334.4K	101.4K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Receivables	0.0	222.7K	0.0	0.0	0.0	0.0	0.0	26.2K	39.5K	76.6K	18.4K	25.8K	11.1K
Inventory	0.0	214.7K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	6.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	144.1K	245K	170.9K
Other Current Assets	1M	316.4K	159.3K	390.4K	135.1K	1.3M	365K	280.2K	1M	1.2M	0.0	0.0	0.0
Total Current Assets	4.6M	19.6M	4.2M	14.7M	5.7M	11.8M	2.8M	4M	7M	7.9M	6.3M	2M	4.3M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	685.2K	322.5K	203K	418.5K	617.1K	150K	2K	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill	10.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.1K	28.4K	40.3K	36K	0.0	0.0
Goodwill & Intangible Assets	10.7M	0.0	0.0	0.0	0.0	0.0	0.0	12.1K	28.4K	40.3K	36K	0.0	0.0
Other Non-Current Assets	11.3M	33.8K	0.0	33.8K	103.9K	1.6M	179K	0.0	0.0	0.0	0.0	550.1K	0.0
Total Non-Current Assets	22.7M	356.3K	203K	452.3K	721K	1.8M	181K	12.1K	28.4K	40.3K	36K	550.1K	0.0
Total Assets	27.4M	20M	4.4M	15.2M	6.4M	13.5M	2.9M	4M	7.1M	7.9M	6.4M	2.6M	4.3M
LIABILITIES
CURRENT LIABILITIES
Total Payables	0.0	3.2M	1.9M	1.9M	6M	2.2M	2M	1.7M	1.5M	1.3M	627.4K	0.0	140.5K
Accounts Payable	0.0	3.2M	1.9M	1.9M	413.8K	2.2M	2M	1.7M	1.5M	1.3M	627.4K	0.0	140.5K
Other Payables	0.0	0.0	0.0	0.0	5.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	855.7K	1.6M	163.7K	36.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short Term Debt	199K	0.0	0.0	0.0	644.1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	159.8K	20.8K	117.5K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	5.7M	1.2M	137K	675K	456K	561K	664K	325.2K	160.4K	33.1K	0.0	853.1K	109K
Total Current Liabilities	5.9M	5.3M	3.6M	2.9M	7.2M	2.8M	2.7M	2.1M	1.6M	1.3M	627.4K	853.1K	249.5K
NON-CURRENT LIABILITIES
Long Term Debt	303.6K	0.0	2.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	272.4K
Deferred Tax Liabilities (Non-Current)	197.9K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	182K	0.0	0.0	1.1K	28.1K	869.6K	2.5M	4.6M
Total Non-Current Liabilities	501.5K	42.7K	2.3M	20.7K	0.0	182K	0.0	0.0	1.1K	28.1K	869.6K	2.5M	4.9M
Capital Lease Obligations	0.0	202.5K	20.8K	138.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	6.4M	5.4M	5.9M	2.9M	7.2M	3M	2.7M	2.1M	1.6M	1.3M	1.5M	3.4M	5.1M
SHAREHOLDERS' EQUITY
Preferred Stock	278.5K	278.5K	8.1K	8.1K	4.7K	14.9M	4.8M	5M	6.4M	6.4M	6.6M	278.5K	0.0
Common Stock	59.3K	42.3K	6.8K	4.5K	4.5K	33K	11K	3.8K	23K	14.5K	11.2K	39.5K	31.5K
Additional Paid-In Capital	161.8M	125.4M	86.9M	71.4M	48.7M	106.8M	65.1M	51M	43.2M	36.7M	28.8M	17.4M	8.8M
Retained Earnings	-141.2M	-111.1M	-88.5M	-59.2M	-49.5M	-111.2M	-69.7M	-60.6M	-52.4M	-41.1M	-32.2M	-18.6M	-15.9M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	21K	21K	6.6M	8.3M	4.6M	1.7M	110.6K	6.2M
Total Stockholders' Equity	20.9M	14.6M	-1.6M	12.3M	-747.8K	10.6M	263K	2M	5.4M	6.6M	4.9M	-821.5K	-818K
Total Equity	20.9M	14.6M	-1.6M	12.3M	-747.8K	10.6M	263K	2M	5.4M	6.6M	4.9M	-821.5K	-818K
SUMMARY
Total Liabilities & Equity	27.4M	20M	4.4M	15.2M	6.4M	13.5M	2.9M	4M	7.1M	7.9M	6.4M	2.6M	4.3M
Total Debt	502.7K	202.5K	2.3M	138.2K	644.1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	272.4K
Net Debt	-3.1M	-12.5M	-1.3M	-14.1M	-4.9M	-10.5M	-2.4M	-3.7M	-6M	-6.6M	-6.2M	-1.8M	-3.9M
Shares Outstanding	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435	50,075,435

SEC Filings

HURA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 29, 2026	May 26, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 15, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 15, 2026	May 15, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	April 30, 2026	December 31, 2025	2025	View Filing
8-K/A 8-K/A 2026 (Amended) N/A	April 30, 2026	April 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 22, 2026	April 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 02, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 01, 2026	April 01, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 31, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 30, 2026	January 29, 2026	2026	View Filing

Showing 1 to 10 of 335 filings

Related Guides

Blog Categories

Continue your HURA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.